Related Experiment Video
Updated: May 18, 2026
07:55
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Application of IL-2 therapy to target T regulatory cell function
1Laboratory of Immunology, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. eshevach@niaid.nih.gov
Trends in Immunology
|September 7, 2012
Summary
Interleukin-2 (IL-2) supports regulatory T cell (Treg) survival and function. Modulating IL-2 delivery via antibody complexes may offer therapeutic benefits for autoimmune and inflammatory diseases.
Area of Science:
- Immunology
- Cell Biology
Background:
- Interleukin-2 (IL-2) is a cytokine crucial for T cell proliferation.
- IL-2 primarily drives CD8(+) T cell expansion and differentiation.
- Regulatory T cells (Tregs) are vital for immune homeostasis and express the complete IL-2 receptor.
Purpose of the Study:
- To investigate the role of IL-2 in Treg cell function.
- To explore the therapeutic potential of exogenous IL-2 in autoimmune and inflammatory conditions.
- To examine targeted delivery strategies for IL-2 using antibody complexes.
Main Methods:
- Analysis of IL-2's effects on T cell subsets in vitro and in vivo.
- Assessment of Treg cell dependency on IL-2 for survival and function.
- Development and evaluation of IL-2-antibody complexes for targeted delivery.
Main Results:
- IL-2 promotes CD8(+) T cell growth but has limited impact on CD4(+) T cell function.
- Treg cells critically depend on IL-2 for their survival and function.
- Exogenous IL-2 can increase Treg cell populations in vivo.
- IL-2-antibody complexes enable targeted delivery to specific immune cell populations.
Conclusions:
- IL-2 is essential for regulatory T cell (Treg) maintenance and activity.
- Targeted delivery of IL-2 using antibody complexes offers a promising strategy for treating immune-mediated diseases.
- Augmenting Treg cell numbers with IL-2 may hold therapeutic value for autoimmune and inflammatory disorders.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.